



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Ye, *et al.*

Appl. No.: 10/755,854

Filed: January 13, 2004

For: **Eosinophil-Derived Neurotoxin as a  
Marker for Ovarian Cancer**

Art Unit: 1642

Examiner: J. Tidwell

Atty. Dkt.: 7570/80962

**Second Supplemental Information Disclosure Statement**

Commissioner of Patents  
U.S. Patent and Trademark Office  
Customer Service Window, **MS Amendment**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents, with the exception of United States patents, are also enclosed.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicants do not believe any fees are due for the submission of this Information Disclosure Statement. However, the Director is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo


Michael A. Sanzo

Reg. No. 36,912

Attorney for Applicants

Date June 8, 2006  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013

<p>LIST OF REFERENCES CITED BY APPLICANT</p> <p>(Use several sheets if necessary)</p>				Atty. Docket No.: 7570/80962		Appl. No.: 10/755,854	
				Applicant(s) Ye, et al.			
				Filing Date: January 13, 2004		Group: 1642	



U.S. PATENT DOCUMENTS

Examiner Initial	A	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A 1	6,675,104	Jan. 6, 2004	Paulse, et al.	702	22	Nov. 15, 2001
	A 2	2003/0087250	May 8, 2003	Monahan, et al.	435	6	Mar. 14, 2002
	A 3						
	A 4						
	A 5						
	A 6						
	A 7						
	A 8						
	A 9						
	A 10						
	A 11						
	A 12						
	A 13						
	A 14						
	A 15						
	A 16						
	A 17						
	A 18						
	A 19						
	A 20						
	A 21						
	A 22						
	A 23						
	A 24						
	A 25						
	A 26						
	A 27						

Examiner	Date Considered
----------	-----------------

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		Atty. Docket No.: 7570/80962	Appl. No.: 10/755,854
		Applicant(s) Ye, et al.	
		Filing Date: January 13, 2004	Group: 1642
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
Examiner Initial			
	C 1	BRAKORA, et al., "Utility of Osteopontin as a Biomarker in Recurrent Epithelial Ovarian Cancer," <i>Gynaecologic Oncology</i> 93:361-365 (2004).	
	C 2	FURGER, et al., "The Functional and Clinical Roles of Osteopontin in Cancer and Metastasis," <i>Curr. Mol. Med.</i> 1:621-632 (2001).	
	C 3	SCHORGE, et al., "Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer," <i>Clin. Cancer Res.</i> 10:3474-3478 (2004).	
	C 4		
	C 5		
	C 6		
	C 7		
	C 8		
	C 9		
	C 10		
	C 11		
	C 12		
	C 13		
	C 14		
	C 15		
	C 16		
	C 17		
	C 18		
	C 19		
Examiner		Date Considered	